Zentalis Pharmaceuticals, Inc.
ZNTL
$1.77
-$0.04-2.21%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Net Income | 27.68% | 21.55% | 115.93% | -10.82% | -2.07% |
Total Depreciation and Amortization | -7.76% | -4.94% | -10.00% | -6.13% | -7.20% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -74.01% | 1.68% | -361.78% | -26.97% | 4.80% |
Change in Net Operating Assets | -251.87% | 373.02% | -305.70% | 157.80% | -50.37% |
Cash from Operations | -13.91% | 55.67% | -5.46% | -8.76% | -16.46% |
Capital Expenditure | 100.00% | 43.26% | -- | -8.13% | 94.52% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 141.11% | -52.76% | 46.21% | -256.97% | -641.38% |
Cash from Investing | 141.08% | -52.71% | 46.11% | -253.62% | -686.73% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -70.23% | -100.00% | -33.51% | -100.00% | -47.54% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -70.23% | -100.00% | -98.12% | -100.00% | -47.54% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 102.75% | -100.28% | 241.08% | -16,057.34% | -1,137.35% |